Kalyra Pharmaceuticals is a drug discovery company that specializes in utilization of innovative substituent groups to enhance the drug-like properties of drug candidates. Kalyra has developed proprietary chemical building blocks, or bioisosteres, to enable efficient drug reconstruction.
Using Kalyra’s bioisosteres, we are able to create drugs with improved properties at lower risk, cost and in less time than traditional drug development. Our technology can be applied to a wide range of molecules across all therapeutic areas, and is applicable to approved drugs as well as to novel targets.
Kalyra has a number of programs which are rapidly progressing through non-clinical development in support of clinical proof of concept trials. These include a new non-addictive therapy for pain management, new treatments for drug resistant microbial infection, and emerging diseases such as fibrosis.